{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:25:43Z","timestamp":1762431943472,"version":"3.40.5"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clml.2020.12.007","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T06:24:41Z","timestamp":1608186281000},"page":"e415-e422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0144-1185","authenticated-orcid":false,"given":"Jonathan","family":"Feld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis R.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamala C.","family":"Navada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.12.007_bib1","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.007_bib2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.12.007_bib4","doi-asserted-by":"crossref","first-page":"CT184","DOI":"10.1158\/1538-7445.AM2019-CT184","article-title":"Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed\/refractory (R\/R) acute myeloid leukemia (AML): results from the phase III ADMIRAL trial","volume":"79","author":"Perl","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-018-1047-7","article-title":"Glasdegib: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2020.12.007_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/pr.109.002329","article-title":"Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies","volume":"62","author":"Mimeault","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clml.2020.12.007_bib8","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1021\/jf5005622","article-title":"Cyclopamine: from cyclops lambs to cancer treatment","volume":"62","author":"Lee","year":"2014","journal-title":"J\u00a0Agric Food Chem"},{"key":"10.1016\/j.clml.2020.12.007_bib9","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1101\/gad.1025302","article-title":"Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened","volume":"16","author":"Chen","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2020.12.007_bib10","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1073733","article-title":"Medulloblastoma growth inhibition by hedgehog pathway blockade","volume":"297","author":"Berman","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.clml.2020.12.007_bib11","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.12.007_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Basset-S\u00e9guin","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.12.007_bib13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jdv.14542","article-title":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","volume":"32","author":"Lear","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venerol"},{"key":"10.1016\/j.clml.2020.12.007_bib14","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of hedgehog pathway inhibitor\u2013related adverse events in patients with advanced basal cell carcinoma","volume":"21","author":"Lacouture","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.12.007_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cam4.350","article-title":"Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds","volume":"4","author":"Yang","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2020.12.007_bib16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1523-1747.2000.00951.x","article-title":"Regular articles: conditional disruption of hedgehog signaling pathway defines its critical role in hair development and regeneration","volume":"114","author":"Wang","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clml.2020.12.007_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2012.09.021","article-title":"Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat","volume":"151","author":"Teperino","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.clml.2020.12.007_bib18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2020.12.007_bib19","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clml.2020.12.007_bib20","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1158\/1078-0432.CCR-14-1059","article-title":"Expression of hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects","volume":"21","author":"Wellbrock","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/ml2002423","article-title":"Discovery of PF-04449913, a potent and orally bioavailable inhibitor of Smoothened","volume":"3","author":"Munchhof","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.clml.2020.12.007_bib22","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood.V116.21.1223.1223","article-title":"Human blast crisis leukemia stem cell inhibition with a novel smoothened antagonist","volume":"116","author":"Schairer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib23","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood.V118.21.3776.3776","article-title":"Cycling toward leukemia stem cell elimination wtih a selective sonic hedgehog antagonist","volume":"118","author":"Shih","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib24","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/1078-0432.CCR-12-1777","article-title":"Combination of ponatinib with hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1\u2013positive leukemia","volume":"19","author":"Katagiri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib25","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1158\/1538-7445.AM2011-4504","article-title":"PF-04449913, a small molecule inhibitor of hedgehog signaling, is effective in inhibiting tumor growth in preclinical models","volume":"71","author":"Jackson-Fisher","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/1078-0432.CCR-14-1116","article-title":"A\u00a0phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors","volume":"21","author":"Wagner","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood.V118.21.424.424","article-title":"Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (HH) inhibitor, in patients with select hematologic malignancies","volume":"118","author":"Jamieson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib28","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2352-3026(15)00096-4","article-title":"Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study","volume":"2","author":"Martinelli","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.12.007_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1158\/1538-7445.AM2012-906","article-title":"Gas1 and Kif27 genes are strongly up-regulated biomarkers of hedgehog inhibition (PF-04449913) on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients","volume":"72","author":"Guadagnuolo","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib30","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.V118.21.1429.1429","article-title":"PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients","volume":"118","author":"Papayannidis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib31","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/cas.13285","article-title":"Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies","volume":"108","author":"Minami","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2020.12.007_bib32","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1078-0432.CCR-17-2824","article-title":"Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS","volume":"24","author":"Savona","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib33","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/j.clml.2019.07.111","article-title":"Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: long-term analysis of a phase 2 randomized trial","volume":"19","author":"Papayannidis","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.12.007_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.007_bib35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A\u00a0comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.12.007_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.12.007_bib37","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood-2019-124034","article-title":"Clinical benefit of glasdegib in combination with azacitidine or low-dose cytarabine in patients with acute myeloid leukemia","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib38","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1002\/cncr.33072","article-title":"A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy","volume":"126","author":"Solem","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.12.007_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-020-00929-8","article-title":"Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy","volume":"13","author":"Cortes","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2020.12.007_bib40","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1158\/1078-0432.CCR-19-1986","article-title":"Glasdegib with low-dose cytarabine: a new upfront option for the vulnerable AML patient","volume":"25","author":"Fathi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib41","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/ajh.25238","article-title":"Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results","volume":"93","author":"Cortes","year":"2018","journal-title":"Am J Hematol"},{"issue":"Supp 1","key":"10.1016\/j.clml.2020.12.007_bib42","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2018-99-111239","article-title":"Biomarkers of overall survival and response to glasdegib and intensive or non-intensive chemotherapy in patients with acute myeloid leukemia","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"13 Supplement","key":"10.1016\/j.clml.2020.12.007_bib43","first-page":"LB","article-title":"Analysis of mutations associated with response to glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)","volume":"78","author":"Ching","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2019.02.012","article-title":"Phase 1\/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib","volume":"79","author":"Gerds","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.12.007_bib45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.leukres.2019.03.008","article-title":"A\u00a0phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)","volume":"81","author":"Sallman","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.12.007_bib46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/bjh.15571","article-title":"Safety and efficacy of vismodegib in relapsed\/refractory acute myeloid leukaemia: results of a phase Ib trial","volume":"185","author":"Bixby","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.12.007_bib47","first-page":"2629","article-title":"Phase I\/Ib study of azacitidine and hedgehog pathway inhibition with sonidegib (LDE225) in myeloid malignancies","volume":"130","author":"Tibes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib48","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood-2018-99-113529","article-title":"Addition of the SMO inhibitor sonidegib to azacitidine in patients with higher risk myelodysplastic syndrome (MDS) who failed to respond or lost response to AZA alone: results of a phase 1-2 add-on study by the GFM","volume":"132","author":"Vey","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib49","first-page":"73","article-title":"Phase 1b study of glasdegib (PF-04449913) in combination with azacitidine in patients with higher risk myelodysplastic syndrome, oligoblastic acute myeloid leukemia, or chronic myelomonocytic leukemia","volume":"101","author":"Borate","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.12.007_bib50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2019-124050","article-title":"A\u00a0phase 1b study of glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia","volume":"134","author":"Sekeres","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib51","doi-asserted-by":"crossref","first-page":"TPS7073","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7073","article-title":"Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia","volume":"36","author":"Jorge","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.007_bib52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/blood-2019-127418","article-title":"A\u00a0phase 2 study of glasdegib for the treatment of acute myeloid leukemia and myelodysplastic syndrome patients with high risk of post-allogeneic stem cell transplantation relapse","volume":"134","author":"Kent","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib53","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1182\/blood-2012-01-403428","article-title":"Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease","volume":"120","author":"Zerr","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib54","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/bloodadvances.2017011239","article-title":"Phase 1 study of the hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease","volume":"1","author":"DeFilipp","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.12.007_bib55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2018-99-113915","article-title":"Hedgehog pathway inhibitor for treatment of steroid-refractory sclerodermatous chronic graft-versus-host disease (GVHD)","volume":"132","author":"Gupta","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.12.007_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.12.007_bib58","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.12.007_bib59","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","article-title":"FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia","volume":"15","author":"Norsworthy","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.12.007_bib60","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.clml.2019.07.114","article-title":"Glasdegib with LDAC in newly diagnosed patients with acute myeloid leukemia (AML) unsuitable for intensive chemotherapy: effects on transfusions and marrow recovery vs LDAC alone","volume":"19","author":"Wang","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.12.007_bib61","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/j.clml.2019.07.116","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase 2 randomized trial","volume":"19","author":"Heuser","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.12.007_bib62","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.2217\/fon-2019-0373","article-title":"Glasdegib plus intensive\/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 phase III trials","volume":"15","author":"Cortes","year":"2019","journal-title":"Future Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020310132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020310132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:36:33Z","timestamp":1730529393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020310132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2152265020310132"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}